SMT201900367T1 - Composizioni monovalenti per il legame a cd28 e metodi di utilizzo - Google Patents

Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Info

Publication number: SMT201900367T1
Authority: SM; San Marino
Prior art keywords: binding; methods; monovalent; compositions; compositions monovalent
Prior art date: 2008-07-18

Application number

SM20190367T

Other languages

English (en)

Inventor

Murray Mckinnon

Brendan Classon

Steve Holmes

Olga Ignatovich

Christopher Plummer

Steve Grant

Steven G Nadler

Suzanne J Suchard

Original Assignee

Bristol Myers Squibb Co

Domantis Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-18

Filing date

2009-07-17

Publication date

2019-09-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201900367(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-07-17 Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co

2019-09-09 Publication of SMT201900367T1 publication Critical patent/SMT201900367T1/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Hematology (AREA)

SM20190367T 2008-07-18 2009-07-17 Composizioni monovalenti per il legame a cd28 e metodi di utilizzo SMT201900367T1 (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8207808P	2008-07-18	2008-07-18
US16212109P	2009-03-20	2009-03-20
EP13185422.6A EP2700651B1 (en)	2008-07-18	2009-07-17	Compositions monovalent for CD28 binding and methods of use

Publications (1)

Publication Number	Publication Date
SMT201900367T1 true SMT201900367T1 (it)	2019-09-09

Family

ID=41226147

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SM20190367T SMT201900367T1 (it)	2008-07-18	2009-07-17	Composizioni monovalenti per il legame a cd28 e metodi di utilizzo
SM201600090T SMT201600090B (it)	2008-07-18	2016-03-29	Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SM201600090T SMT201600090B (it)	2008-07-18	2016-03-29	Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Country Status (29)

Country	Link
US (6)	US8168759B2 (it)
EP (2)	EP2321352B1 (it)
JP (3)	JP5675608B2 (it)
KR (2)	KR101791372B1 (it)
CN (2)	CN102159590A (it)
AR (1)	AR072571A1 (it)
AU (1)	AU2009270726B2 (it)
CA (1)	CA2731220C (it)
CL (2)	CL2011000117A1 (it)
CO (1)	CO6341641A2 (it)
CY (1)	CY1121796T1 (it)
DK (2)	DK2700651T3 (it)
EA (1)	EA024585B1 (it)
ES (2)	ES2562629T3 (it)
HR (2)	HRP20160329T1 (it)
HU (2)	HUE045249T2 (it)
IL (2)	IL210413A (it)
LT (1)	LT2700651T (it)
ME (1)	ME02396B (it)
MX (1)	MX2011000501A (it)
NZ (1)	NZ590343A (it)
PE (2)	PE20110385A1 (it)
PL (2)	PL2700651T3 (it)
PT (2)	PT2700651T (it)
RS (2)	RS58904B1 (it)
SI (2)	SI2321352T1 (it)
SM (2)	SMT201900367T1 (it)
TW (2)	TWI450725B (it)
WO (1)	WO2010009391A1 (it)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103254309B (zh)	2005-05-18	2017-09-26	埃博灵克斯股份有限公司	针对肿瘤坏死因子α的改进的纳米体TM
US20110097339A1 (en) *	2008-07-18	2011-04-28	Domantis Limited	Compositions monovalent for CD28 binding and methods of use
US8168759B2 (en) *	2008-07-18	2012-05-01	Bristol-Myers Squibb Company	Compositions monovalent for CD28 binding and methods of use
JP5745432B2 (ja) *	2009-02-25	2015-07-08	ネクステラアーエス	シグナル配列非依存性ｐＩＸファージディスプレイ
FR2951176A1 (fr) *	2009-10-09	2011-04-15	Tcl Pharma	Ligands monovalents du recepteur cd28 humain
WO2011101791A1 (en) *	2010-02-18	2011-08-25	Tcl Pharma	Anti-cd28 humanized antibodies
EP2361935A1 (en) *	2010-02-18	2011-08-31	TcL Pharma	Anti-CD28 humanized antibodies
JP2013534520A (ja)	2010-06-08	2013-09-05	ジェネンテック，インコーポレイテッド	システイン操作抗体及びコンジュゲート
JP5768022B2 (ja) *	2012-03-19	2015-08-26	株式会社東芝	メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Pegylated domain antibodies monovalent for cd28 binding and methods of use
CN106029682B (zh)	2013-12-27	2021-04-13	中外制药株式会社	等电点低的抗体的纯化方法
KR20160124912A (ko)	2014-03-19	2016-10-28	브리스톨-마이어스 스큅 컴퍼니	Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법
AU2015314826A1 (en)	2014-09-12	2017-03-02	Genentech, Inc.	Cysteine engineered antibodies and conjugates
SG11201702383SA (en) *	2014-09-30	2017-04-27	Bristol Myers Squibb Co	Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28
US20190086405A1 (en)	2016-03-16	2019-03-21	Bristol-Myers Squibb Company	Methods of diagnosing and treating lupus
EP3551047A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en)	2017-03-30	2021-05-13	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
MY200973A (en)	2017-04-11	2024-01-26	Inhibrx Inc	Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
CN112074539B (zh)	2018-03-15	2025-01-24	比昂生物制剂公司	降低可溶性免疫受体cd28的方法和组合物
IL323061A (en)	2018-04-11	2025-10-01	Inhibrx Biosciences Inc	Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
KR20210035805A (ko)	2018-06-15	2021-04-01	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019288635A1 (en) *	2018-06-22	2021-01-21	Junten Bio Co., Ltd.	Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
CA3106115A1 (en) *	2018-07-08	2020-01-16	Specifica Inc.	Antibody libraries with maximized antibody developability characteristics
CN112789294A (zh)	2018-07-24	2021-05-11	印希比股份有限公司	含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
ES3038185T3 (en)	2018-08-03	2025-10-10	Bristol Myers Squibb Co	Methods for detecting anti-drug antibodies
CN116726362A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
AU2020234111A1 (en) *	2019-03-14	2021-10-14	Biond Biologics Ltd.	Small shedding blocking agents
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
ES2821599A1 (es) *	2019-10-24	2021-04-26	Univ Del Pais Vasco / Euskal Herriko Unibertsitatea	Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CN114901312A (zh) *	2019-12-02	2022-08-12	比昂生物制剂公司	Mmp抑制的用途
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
US20230114107A1 (en)	2019-12-17	2023-04-13	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN115380047A (zh) *	2020-01-29	2022-11-22	印希比股份有限公司	Cd28单结构域抗体及其多价和多特异性构建体
US20230355804A1 (en)	2020-06-29	2023-11-09	Flagship Pioneering Innovations V, Inc.	Viruses engineered to promote thanotransmission and their use in treating cancer
CA3187850A1 (en) *	2020-08-04	2022-02-10	Bryan Glaser	Pd-l1 binding agents and uses thereof
CA3214085A1 (en)	2021-03-31	2022-10-06	Darby Rye Schmidt	Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko)	2021-06-29	2024-02-28	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
JP2024532970A (ja) *	2021-09-06	2024-09-11	ビオンドバイオロジックスリミテッド	Ｃｄ２８シェディング遮断剤
TW202400659A (zh) *	2022-05-04	2024-01-01	美商詹努克斯治療有限公司	經腫瘤活化之靶向ｃｄ２８及ｐｄ－ｌ１之多特異性抗體及其使用方法
WO2023215560A1 (en)	2022-05-05	2023-11-09	Atoosa Corporation	Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2023215498A2 (en) *	2022-05-05	2023-11-09	Modernatx, Inc.	Compositions and methods for cd28 antagonism
EP4572772A1 (en)	2022-08-17	2025-06-25	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023356326A1 (en)	2022-10-06	2025-03-27	Bicara Therapeutics Inc.	Multispecific proteins and related methods
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2024211211A1 (en)	2023-04-03	2024-10-10	Regeneron Pharmaceuticals, Inc.	Methods of improving transplant survival using il-2 receptor gamma chain antibodies
US12311033B2 (en)	2023-05-31	2025-05-27	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en)	2023-10-05	2025-04-24	Capstan Therapeutics, Inc.	Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en)	2024-02-22	2025-10-02	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4839295A (en)	1984-06-08	1989-06-13	Pierce Chemical Company	Measurement of protein using bicinchoninic acid
US5977307A (en)	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
CA2046830C (en)	1990-07-19	1999-12-14	Patrick P. Deluca	Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6005079A (en)	1992-08-21	1999-12-21	Vrije Universiteit Brussels	Immunoglobulins devoid of light chains
EP0656946B2 (en)	1992-08-21	2010-03-31	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
SE9400088D0 (sv)	1994-01-14	1994-01-14	Kabi Pharmacia Ab	Bacterial receptor structures
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
GB9416721D0 (en)	1994-08-18	1994-10-12	Short Brothers Plc	A bias yarn assembly forming device
DK0814778T3 (da)	1995-03-10	2001-09-17	Roche Diagnostics Gmbh	Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf
CA2229043C (en)	1995-08-18	2016-06-07	Morphosys Gesellschaft Fur Proteinoptimierung Mbh	Protein/(poly)peptide libraries
WO1998058965A2 (en)	1997-06-20	1998-12-30	Innogenetics N.V.	B7-binding molecules for treating immune diseases
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
DE69921636T2 (de)	1998-04-20	2005-11-03	Genzyme Corp., Cambridge	Medikamentöse verabreichung von proteinen aus polymergemischen
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
JP2003502024A (ja)	1999-05-14	2003-01-21	メディカルリサーチカウンシル	タンパク質骨格および単量体ポリペプチドを多量体化するためのその使用
US20020006403A1 (en)	1999-12-14	2002-01-17	Xue-Zhong Yu	CD28-specific antibody compositions for use in methods of immunosuppression
EP1345969B1 (fr) *	2000-12-26	2010-08-11	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Anticorps anti-cd28
US20080095774A1 (en) *	2001-02-16	2008-04-24	Wyeth	Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en)	2001-02-16	2009-05-12	Genetics Institute Llc	Method for downmodulating immune response in type I diabetes
US20030157561A1 (en)	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
US20050089932A1 (en)	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
DE60237282D1 (de)	2001-06-28	2010-09-23	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
CA2457636C (en)	2001-08-10	2012-01-03	Aberdeen University	Antigen binding domains
WO2003031611A2 (en)	2001-10-05	2003-04-17	Cangene Corporation	Phagemid display system
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
DE10156482A1 (de) *	2001-11-12	2003-05-28	Gundram Jung	Bispezifisches Antikörper-Molekül
DK1517921T3 (da)	2002-06-28	2006-10-09	Domantis Ltd	Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP3299393A1 (en)	2002-11-08	2018-03-28	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2511910A1 (en)	2002-12-27	2004-07-15	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2522586C (en)	2003-05-31	2017-02-21	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004284090A1 (en)	2003-10-24	2005-05-06	Avidia, Inc.	LDL receptor class A and EGF domain monomers and multimers
CN100376599C (zh)	2004-04-01	2008-03-26	北京安波特基因工程技术有限公司	基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
CN101061140B (zh) *	2004-09-17	2015-07-01	多曼蒂斯有限公司	单价结合cd40l的组合物和应用方法
GB0614093D0 (en)	2006-07-14	2006-08-23	Bae Systems Plc	Deployable antenna system
AU2007331672A1 (en) *	2006-12-15	2008-06-19	Ablynx N.V.	Amino acid sequences that modulate the interaction between cells of the immune system
US8168759B2 (en) *	2008-07-18	2012-05-01	Bristol-Myers Squibb Company	Compositions monovalent for CD28 binding and methods of use
AU2009284113B2 (en)	2008-08-21	2015-05-14	Octapharma Ag	Recombinantly produced human factor VIII and IX
KR20160124912A (ko) *	2014-03-19	2016-10-28	브리스톨-마이어스 스큅 컴퍼니	Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법
SG11201702383SA (en) *	2014-09-30	2017-04-27	Bristol Myers Squibb Co	Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

2009
- 2009-07-17 US US12/505,166 patent/US8168759B2/en active Active
- 2009-07-17 PE PE2011000053A patent/PE20110385A1/es active IP Right Grant
- 2009-07-17 SM SM20190367T patent/SMT201900367T1/it unknown
- 2009-07-17 AR ARP090102734A patent/AR072571A1/es active IP Right Grant
- 2009-07-17 RS RS20190631A patent/RS58904B1/sr unknown
- 2009-07-17 PT PT13185422T patent/PT2700651T/pt unknown
- 2009-07-17 KR KR1020167025702A patent/KR101791372B1/ko not_active Expired - Fee Related
- 2009-07-17 ME MEP-2016-76A patent/ME02396B/me unknown
- 2009-07-17 TW TW098124305A patent/TWI450725B/zh not_active IP Right Cessation
- 2009-07-17 ES ES09790582.2T patent/ES2562629T3/es active Active
- 2009-07-17 PT PT97905822T patent/PT2321352E/pt unknown
- 2009-07-17 HR HRP20160329TT patent/HRP20160329T1/hr unknown
- 2009-07-17 PE PE2014000192A patent/PE20140852A1/es not_active Application Discontinuation
- 2009-07-17 HU HUE13185422A patent/HUE045249T2/hu unknown
- 2009-07-17 DK DK13185422.6T patent/DK2700651T3/da active
- 2009-07-17 NZ NZ590343A patent/NZ590343A/xx unknown
- 2009-07-17 TW TW101147598A patent/TW201336510A/zh unknown
- 2009-07-17 RS RS20160200A patent/RS54675B1/sr unknown
- 2009-07-17 SI SI200931383T patent/SI2321352T1/sl unknown
- 2009-07-17 AU AU2009270726A patent/AU2009270726B2/en not_active Ceased
- 2009-07-17 CA CA2731220A patent/CA2731220C/en not_active Expired - Fee Related
- 2009-07-17 ES ES13185422T patent/ES2730727T3/es active Active
- 2009-07-17 PL PL13185422T patent/PL2700651T3/pl unknown
- 2009-07-17 EA EA201100239A patent/EA024585B1/ru not_active IP Right Cessation
- 2009-07-17 CN CN2009801358711A patent/CN102159590A/zh active Pending
- 2009-07-17 DK DK09790582.2T patent/DK2321352T3/en active
- 2009-07-17 JP JP2011518935A patent/JP5675608B2/ja not_active Expired - Fee Related
- 2009-07-17 CN CN201610344002.1A patent/CN105936648B/zh active Active
- 2009-07-17 HU HUE09790582A patent/HUE029982T2/en unknown
- 2009-07-17 MX MX2011000501A patent/MX2011000501A/es active IP Right Grant
- 2009-07-17 EP EP09790582.2A patent/EP2321352B1/en active Active
- 2009-07-17 LT LTEP13185422.6T patent/LT2700651T/lt unknown
- 2009-07-17 KR KR1020117003660A patent/KR101660057B1/ko active Active
- 2009-07-17 PL PL09790582T patent/PL2321352T3/pl unknown
- 2009-07-17 WO PCT/US2009/050985 patent/WO2010009391A1/en not_active Ceased
- 2009-07-17 EP EP13185422.6A patent/EP2700651B1/en active Active
- 2009-07-17 SI SI200931964T patent/SI2700651T1/sl unknown
2010
- 2010-12-30 IL IL210413A patent/IL210413A/en active IP Right Grant
2011
- 2011-01-18 CL CL2011000117A patent/CL2011000117A1/es unknown
- 2011-02-15 CO CO11017973A patent/CO6341641A2/es active IP Right Grant
2012
- 2012-03-09 US US13/416,033 patent/US8454959B2/en not_active Expired - Fee Related
- 2012-03-09 US US13/415,914 patent/US9085629B2/en active Active
- 2012-08-31 CL CL2012002428A patent/CL2012002428A1/es unknown
2014
- 2014-12-24 JP JP2014261305A patent/JP5876134B2/ja not_active Expired - Fee Related
2015
- 2015-06-16 US US14/740,709 patent/US9908937B2/en active Active
2016
- 2016-01-20 JP JP2016009024A patent/JP6058833B2/ja not_active Expired - Fee Related
- 2016-03-29 SM SM201600090T patent/SMT201600090B/it unknown
2017
- 2017-03-21 IL IL251320A patent/IL251320B/en active IP Right Grant
2018
- 2018-01-12 US US15/870,121 patent/US10919965B2/en active Active
2019
- 2019-05-28 HR HRP20190966TT patent/HRP20190966T1/hr unknown
- 2019-07-09 CY CY20191100722T patent/CY1121796T1/el unknown
2020
- 2020-11-02 US US17/086,565 patent/US12012452B2/en active Active

Also Published As

Publication number	Publication date
CN102159590A (zh)	2011-08-17
HRP20160329T1 (hr)	2016-04-22
US8454959B2 (en)	2013-06-04
LT2700651T (lt)	2019-06-25
CO6341641A2 (es)	2011-11-21
EP2700651A1 (en)	2014-02-26
CL2011000117A1 (es)	2011-06-17
ES2730727T3 (es)	2019-11-12
TW201006494A (en)	2010-02-16
CA2731220C (en)	2017-10-10
CY1121796T1 (el)	2020-07-31
ME02396B (me)	2016-08-31
EA201100239A1 (ru)	2011-10-31
EA024585B1 (ru)	2016-10-31
SI2321352T1 (sl)	2016-04-29
CL2012002428A1 (es)	2013-01-11
HRP20190966T1 (hr)	2019-07-26
JP5675608B2 (ja)	2015-02-25
US9908937B2 (en)	2018-03-06
HK1155178A1 (zh)	2012-05-11
IL251320A0 (en)	2017-05-29
JP5876134B2 (ja)	2016-03-02
DK2321352T3 (en)	2016-04-04
TW201336510A (zh)	2013-09-16
AU2009270726A1 (en)	2010-01-21
US10919965B2 (en)	2021-02-16
TWI450725B (zh)	2014-09-01
DK2700651T3 (da)	2019-07-22
AU2009270726B2 (en)	2015-07-09
US20100028354A1 (en)	2010-02-04
IL210413A0 (en)	2011-03-31
EP2321352B1 (en)	2016-01-06
JP2011528551A (ja)	2011-11-24
CN105936648A (zh)	2016-09-14
EP2700651B1 (en)	2019-04-10
SI2700651T1 (sl)	2019-08-30
HUE045249T2 (hu)	2019-12-30
CA2731220A1 (en)	2010-01-21
US20150299321A1 (en)	2015-10-22
RS54675B1 (sr)	2016-08-31
PE20110385A1 (es)	2011-06-22
KR101660057B1 (ko)	2016-09-26
PL2700651T3 (pl)	2019-09-30
AR072571A1 (es)	2010-09-08
PT2321352E (pt)	2016-03-18
IL251320B (en)	2019-01-31
US9085629B2 (en)	2015-07-21
PT2700651T (pt)	2019-06-19
JP6058833B2 (ja)	2017-01-11
KR20110041527A (ko)	2011-04-21
US20130109846A1 (en)	2013-05-02
US12012452B2 (en)	2024-06-18
WO2010009391A1 (en)	2010-01-21
RS58904B1 (sr)	2019-08-30
KR101791372B1 (ko)	2017-10-27
CN105936648B (zh)	2020-06-16
US20120201814A1 (en)	2012-08-09
US20210047414A1 (en)	2021-02-18
IL210413A (en)	2017-04-30
HUE029982T2 (en)	2017-04-28
NZ590343A (en)	2012-10-26
US8168759B2 (en)	2012-05-01
EP2321352A1 (en)	2011-05-18
US20180142023A1 (en)	2018-05-24
JP2016063830A (ja)	2016-04-28
KR20160113322A (ko)	2016-09-28
JP2015120695A (ja)	2015-07-02
PE20140852A1 (es)	2014-07-14
MX2011000501A (es)	2011-05-23
SMT201600090B (it)	2016-04-29
PL2321352T3 (pl)	2016-06-30
ES2562629T3 (es)	2016-03-07

Publication	Publication Date	Title
IL251320A0 (en)	2017-05-29	Monovalent compounds for binding cd28 and methods of use
IL208284A0 (en)	2010-12-30	Compositions and methods for preparing and using same
IL210153A0 (en)	2011-03-31	Nutrigenomics methods and compositions
EP2334185A4 (en)	2011-09-21	COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
SG10201701954QA (en)	2017-05-30	Anti-cxcr1 compositions and methods
GB0819530D0 (en)	2008-12-03	Methods and compositions
IL210559A0 (en)	2011-03-31	Novel compositions and methods
EP2231665A4 (en)	2012-04-25	NEW COMPOSITIONS AND METHODS OF USE
IL208445A0 (en)	2010-12-30	Compositions and methods for immunotherapy
IL210588A0 (en)	2011-03-31	Novel compositions and methods
IL201364A0 (en)	2010-06-30	Gas-effusing compositions and methods of making and using same
GB0817585D0 (en)	2008-11-05	Novel compositions and methods
ZA201102207B (en)	2011-11-30	Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en)	2010-12-30	Apoaequorin-containing compositions and methods of using same
GB0811250D0 (en)	2008-07-30	Methods and compositions
GB0818399D0 (en)	2008-11-12	Methods and compositions
GB0803464D0 (en)	2008-04-02	Methods and compositions
GB0816534D0 (en)	2008-10-15	Compositions and methods
GB0811152D0 (en)	2008-07-23	Methods and compositions